Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiling of Venetoclax-treated HL-60 cells

ABSTRACT: Venetoclax is a selective BCL-2 inhibitor with antileukemic activity. To investigate the transcriptional alterations induced by Venetoclax in human acute myeloid leukemia cells, HL-60 cells were treated with Venetoclax for 48 h and subjected to whole-transcriptome expression profiling using the GeneChip PrimeView Human Gene Expression Array. HL-60 cells were treated with 9.788 μM Venetoclax for 48 h. HL-60 cells without Venetoclax treatment were used as controls. Total RNA was isolated from control and Venetoclax-treated cells, and biotin-labeled cRNA was prepared and hybridized to PrimeView Human Gene Expression Array chips.

ORGANISM(S): Homo sapiens

PROVIDER: GSE344362 | GEO | 2026/08/24

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcription profiling of human HL-60 leukemia cells after treatment with Curcumin and TCDD

Project description:Curcumin has antileukemic potential that is mediated by dfifferent pathways. Because we could not confirm that the Arylhydrocarbonreceptor, a ligand activated transcription factor, is involved in curcumins antileukemic effects, we performed microarray experiments to have an overall screening of the pathways affected by curcumin in HL-60 cells. We identified an involvement of the vitamin D receptor in the effects of curcumin on HL-60 cells by comparing our results with other experiments. Experiment Overall Design: HL-60 cells were treated for 24h with 100 ÂµM curcumin, 10 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), or 0.5 % DMSO as control.

2009-06-01 | E-GEOD-16160 | biostudies-arrayexpress

Gene expression profiling of Venetoclax-treated HL-60 cells

Project description:Gene expression profiling of Venetoclax-treated HL-60 cells

| PRJNA1515305 | ENA

Expression data of HL-60 leukemia cells after treatment with Curcumin and TCDD

2009-05-19 | GSE16160 | GEO

Human HL-60 Cells: all-trans retinoic acid (ATRA) vs. ATRA plus arsenic trioxide (ATO)

Project description:Transcriptional profiling of human leukemia　HL-60 cells comparing ATRA treated HL-60 cells with ATRA plus ATO. Goal was to determine the effects of ATO on ATRA induced differentiation of HL-60 cells.

2015-03-31 | GSE67420 | GEO

The Acetylation proteomics of HL-60 cells in the presence or absence of amiodarone

Project description:To verify the acetylation effect of amiodarone on HL-60 cells, we treated HL-60 cells with 10 渭M amiodarone for 24 h and collected cells for acetylation protein detection

2024-01-16 | PXD048570 | Pride

Shotgun mass-spectrometry of HL-60 cell proteins for spectrum library development

Project description:ATRA-induced differentiation of HL-60 cells was studied using targeted mass-spectrometry including selected reaction monitoring (SRM) and parallel reaction monitoring (PRM) approach. PRM experiment was performed in time-course manner, without peptide standards usage. PRM data was inspected in Skyline 3.1 software. In order to check peptide identity we developed spectrum library based on shotgun mass-spectrometry data, which has been obtained for HL-60 cells protein samples at 0, 3, 24, 48 and 96h after ATRA treatment.

2017-11-09 | PXD006421 | Pride

Gene Expression-Based High Throughput Screening: HL-60 Cell Treatment with Candidate Compounds

Project description:We developed a general approach to small molecule library screening called GE-HTS (Gene Expression-Based High Throughput Screening) in which a gene expression signature is used as a surrogate for cellular states and applied it to the identification of compounds inducing the differentiation of acute myeloid leukemia cells. In screening 1,739 compounds, we prioritized 15 candidate compounds (2 were already confirmed in the literature). We next evaluated the 13 remaining compounds. Eight reliably induced the differentiation signature, and furthermore yielded functional evidence of bona fide differentiation. This data set contains HL-60 cells treated in replicates of 3 with the original 13 selected candidates. It also contains 6 untreated, 6 DMSO treated, 3 ATRA treated, 3 PMA treated, and 3 1,25-dihydroxyvitamin D3 treated HL-60 controls. In addition, it contains 3 neutrophil and 3 monocyte samples from distinct normal human donors and 9 primary patient AML samples. This data set was used to evaluate the whole genome effects of the candidate compounds on HL-60 cells. Keywords = AML Keywords = leukemia Keywords = HL-60 Keywords = chemical genomics Keywords: repeat sample

2004-01-30 | GSE982 | GEO

Ribo-seq of decitabine-treated WT HL-60 cells

Project description:Ribo-seq of decitabine-treated WT HL-60 cells

| PRJNA923627 | ENA

MeRIP-seq of decitabine-treated WT HL-60 cells

Project description:MeRIP-seq of decitabine-treated WT HL-60 cells

| PRJNA923628 | ENA

Human HL-60 Cells: all-trans retinoic acid (ATRA) vs. ATRA plus arsenic trioxide (ATO)

Project description:Transcriptional profiling of human leukemia?HL-60 cells comparing ATRA treated HL-60 cells with ATRA plus ATO. Goal was to determine the effects of ATO on ATRA induced differentiation of HL-60 cells. Two-condition experiment, ATRA vs. ATRA plus ATO treated HL-60 cells.

2015-03-31 | E-GEOD-67420 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data